IDH1 and myelodysplastic syndrome: Mutations in IDH1/2 lead to the accumulation of the oncogenic metabolite 2-hydroxyglutarate (2-HG), which affects cellular differentiation and leads to aberrant epigenetic regulation, which in turn blocks hematopoietic cell differentiation and promotes the progression of MDS to AML.